Contera Pharma announces acquisition by Korean Bukwang Pharmaceutical JM-010 to enter global development for L-DOPA induced dyskinesia Contera Pharma (Copenhagen, Denmark) is pleased to announce that Bukwang Pharmaceutical (Seoul, Korea) has acquired 100% of Contera Pharma from its current shareholders. The shareholders received an undisclosed upfront payment and are entitled to future contingent and royalty […]
Concit Pharma has changed its corporate name to Contera Pharma, effective from 19.11.2013. As of 19.11.2013 Don deBethizy is appointed chairman of the board. Don is the former CEO of Targacept, Inc a public biotech company discovering and developing novel small molecules targeting serious CNS disorders. Don will help the company to explore financing opportunities […]
Concit Pharma paricipated in the Danish Life Sciences Investor Forum in New York on 30.09.2013 to 02.10.2013.
On July 1st Concit Pharma received approval of protocol for the Phase IIa study in L-DOPA induced dyskinesia. The approval is an important milestone and strongly supports Concit Pharma’s development plans.
Concit Pharma will present JM-010 at the Movement Disorder Society meeting in Sydney, Australia June 16-20. The preclinical data suppporting the efficacy and safety of JM-010 as a new drug for treatment of L-DOPA induced dyskinesia will be presented on a poster. A copy of the poster can be obtained upon request (kbh@concitpharma.com).
On October 1st Concit Pharma and Neurobiological Research Unit, Copenhagen National Hospital (Rigshospitalet) has initiated a research project supported by The Danish National Advanced Technology Foundation. The project will during the next two years focus on identification and characterization of new drugs for treatment of L-DOPA induced dysinesia.
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com